Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir

This study has been completed.
Sponsor:
Collaborator:
Vertex Pharmaceuticals Incorporated
Information provided by (Responsible Party):
Tibotec BVBA
ClinicalTrials.gov Identifier:
NCT01253551
First received: December 2, 2010
Last updated: October 13, 2012
Last verified: October 2012
  Purpose

The purpose of this study is to confirm the absence of a clinically relevant interaction between telaprevir and raltegravir at steady-state.Telaprevir is being investigated for the treatment of chronic hepatitis C virus infection, and raltegravir is used to treat HIV infection.


Condition Intervention Phase
Hepatitis C
Drug: Treatment sequence AB
Drug: Treatment sequence BA
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Randomized, Crossover Study in 20 Healthy Subjects to Investigate the Potential Pharmacokinetic Interaction Between Telaprevir and Raltegravir, Both at Steady-state

Resource links provided by NLM:


Further study details as provided by Tibotec BVBA:

Primary Outcome Measures:
  • Blood levels of telaprevir and raltegravir when given alone versus when given together [ Time Frame: Day 7 of Treatment A ] [ Designated as safety issue: No ]
  • Blood levels of telaprevir and raltegravir when given alone versus when given together [ Time Frame: Day 4 of Treatment B ] [ Designated as safety issue: No ]
  • Blood levels of telaprevir and raltegravir when given alone versus when given together [ Time Frame: Day 11 of Treatment B ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percentage of participants with a given adverse event as a measure of safety and tolerability [ Time Frame: From screening to end of study ] [ Designated as safety issue: Yes ]
  • Clinical laboratory abnormalities as a measure of safety and tolerability [ Time Frame: At screening and at 5-7 days and 30-32 days after last dose (Treatment A or B) ] [ Designated as safety issue: Yes ]
  • Clinical laboratory abnormalities as a measure of safety and tolerability [ Time Frame: On Days 1 and 7 (Treatment A) ] [ Designated as safety issue: Yes ]
  • Clinical laboratory abnormalities as a measure of safety and tolerability [ Time Frame: On Days 1, 4, and 11 (Treatment B) ] [ Designated as safety issue: Yes ]
  • Vital signs observed values and changes from baseline as a measure of safety and tolerability [ Time Frame: At screening and at 5-7 days and 30-32 days after last dose (Treatment A or B) ] [ Designated as safety issue: Yes ]
  • Vital signs observed values and changes from baseline as a measure of safety and tolerability [ Time Frame: On Days 1 and 7 (Treatment A) ] [ Designated as safety issue: Yes ]
  • Vital signs observed values and changes from baseline as a measure of safety and tolerability [ Time Frame: On Days 1, 4, and 11 (Treatment B) ] [ Designated as safety issue: Yes ]
  • Physical examination findings and changes from baseline as a measure of safety and tolerability [ Time Frame: At screening, on Day -1 of Treatments A and B, and at 5-7 days and 30-32 days after last dose (Treatment A or B) ] [ Designated as safety issue: Yes ]

Enrollment: 21
Study Start Date: December 2010
Study Completion Date: April 2011
Arms Assigned Interventions
Experimental: 001
Treatment sequence AB Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
Drug: Treatment sequence AB
Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
Experimental: 002
Treatment sequence BA Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
Drug: Treatment sequence BA
Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.

Detailed Description:

This is an open-label, randomized (the order in which you receive the treatment sessions is determined by chance, like tossing a coin), crossover (participants will receive different interventions sequentially during the trial) study in healthy participants to investigate the effect of telaprevir 750 mg, every 8 hours, on the pharmacokinetics (how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body) of raltegravir 400 mg, twice a day, and vice versa. The study population will consist of 20 healthy participants. Each individual participant will receive two treatments: Treatment A (telaprevir 750 mg, every 8 hours, alone, on Days 1 to 6, with a morning dose on Day 7) and Treatment B (raltegravir 400 mg, twice a day, on Days 1 to 10 and telaprevir 750 mg, every 8 hours, on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11). Half of the participants will receive first Treatment A and then Treatment B; the other half will receive first Treatment B and then Treatment A. There will be a washout period of at least 14 days between the 2 sessions. The screening period will be maximum 21 days; the treatment duration will be approximately 4.5 weeks, and the follow-up period will be 30 to 31 days. All study medication will be taken with food. On Day 7 of Treatment A and Day 11 of Treatment B, 9 blood samples will be taken for determination of the levels of telaprevir in the blood. On Days 4 and 11 of Treatment B, 10 blood samples will be taken for determination of the levels of raltegravir in the blood. Predose pharmacokinetic samples will be collected on other days during the treatment sessions. Safety and tolerability will be evaluated throughout the trial by evaluating results of blood and urine analyses, vital signs, physical examinations, electrocardiograms (electrical recording of the heart), drug and alcohol screenings, and by assessing how the participant is feeling. In Treatment A, participants will receive 2 oral tablets of telaprevir 375 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. In Treatment B, participants will receive 1 oral tablet of 400 mg raltegravir twice a day on Days 1 to 10 and 2 oral tablets of 375 mg telaprevir every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy on the basis of physical examination, medical history, vital signs, electrocardiogram and clinical laboratory tests at screening
  • A Body Mass Index of 18.0 to 30.0 kg/m2, extremes included
  • Women must be postmenopausal for at least 2 years, be surgically sterile and should not be breastfeeding
  • Men must agree to use 2 highly effective methods of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of the study drug
  • Be non-smoking for at least 3 months prior to selection.

Exclusion Criteria:

  • Current use of prescription medication, regular treatment with over-the-counter medications (to be stopped no less than 7 days prior to first intake of study medication) or consumption of herbal medications or dietary supplements, vitamins, grapefruit or grapefruit juice, apple juice or orange juice within 14 days before first intake of study medication
  • Consumption of more than 2 units of alcoholic beverages per day or more than 14 units per week (1 unit of alcohol equals 1 glass of beer, 1 glass of wine, 25 mL shot of 40% spirit), consumption of alcohol 72 hours before or after study medication intake, consumption of an average of more than five 240 mL servings of coffee or other caffeinated beverages, eg, tea, cola per day
  • History or evidence of current use of alcohol, barbiturate, amphetamine, recreational or narcotic drug use
  • Received an investigational drug or vaccine or used an investigational medical device within 3 months or 5 half lives (whichever is longer) before the planned start of treatment or having participated previously in a study with telaprevir.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01253551

Sponsors and Collaborators
Tibotec BVBA
Vertex Pharmaceuticals Incorporated
Investigators
Study Director: Tibotec-Virco Virology BVBA Clinical Trial Tibotec BVBA
  More Information

No publications provided

Responsible Party: Tibotec BVBA
ClinicalTrials.gov Identifier: NCT01253551     History of Changes
Other Study ID Numbers: CR017608, VX-950HEP1001
Study First Received: December 2, 2010
Last Updated: October 13, 2012
Health Authority: United States: Food and Drug Administration
USA: FOOD AND DRUG ADMINISTRATION - CENTER FOR DRUG EVALUATION AND RESEARCH

Keywords provided by Tibotec BVBA:
VX-950HEP1001
hepatitis
telaprevir
raltegravir
crossover
healthy volunteers
VX-950.

Additional relevant MeSH terms:
Hepatitis
Hepatitis C
Digestive System Diseases
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
RNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on November 23, 2014